Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED  

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Antibiotic Drugs API  > Emtricitabine CAS 143491-57-0 SM-Q

Emtricitabine CAS 143491-57-0 SM-Q 

Payment Terms: T/T,L/C,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C8H10FN3O3S
Production Capacity: 50 Kilogram/Year
Delivery Date: within 7 days
Molecular Formul: C8H10FN3O3S
CAS NO.: 143491-57-0
Density: 1.829g/cm3
Flash point: 221.889°C
Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Brand: MOSINTER
Molecular Weight: 247.2467
Boiling point: 443.281°C at 760 mmHg
Melting point: 136-140°C
Vapour Pressur: 0mmHg at 25°C

The drug works by inhibiting reverse transcriptase, the enzyme that copies HIV RNA into new viral DNA.

Emtricitabine CAS: 143491-57-0

Molecular Formula

C8H10FN3O3S

Molecular Weight

247.2467

Density

1.829g/cm3

Melting point

136-140°C

Boiling point

443.281°C at 760 mmHg

Refractive index

1.731

Flash point

221.889°C

Vapour Pressur

0mmHg at 25°C


Emtricitabine is indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults

 

HBV infection

Emtricitabine exhibits clinical activity against the hepatitis B virus (HBV). Among individuals with chronic HBV infection, emtricitabine treatment results in significant histologic, virologic, and biochemical improvement. The safety profile of emtricitabine during treatment is similar to that of a placebo. Emtricitabine, however, cures neither HIV nor HBV infection. In a study involving individuals with HBV infection, symptoms of infection returned in 23% of emtricitabine-treated individuals who were taken off therapy. In studies involving individuals with chronic HIV infection, viral replication also resumes when study subjects are taken off therapy.

 

Side effects

In clinical practice, toxicity with emtricitabine is unusual. The most common treatment-related adverse events are diarrhea, headache, nausea, and rash. These symptoms are generally mild to moderate in severity, but they caused 1% of clinical trial patients to give up treatment. Skin discoloration, which is typically reported as hyperpigmentation and usually affects either the palms of the hands or the soles of the feet, is reported in less than 2% of individuals and is almost exclusive to patients of African origin.

Among the more severe side effects patients may experience are a hepatotoxicity or a lactic acidosis.

 

Mechanism of action

Emtricitabine is an analogue of cytidine. The drug works by inhibiting reverse transcriptase, the enzyme that copies HIV RNA into new viral DNA. By interfering with this process, which is central to the replication of HIV, emtricitabine can help to lower the amount of HIV, or "viral load", in a patient's body and can indirectly increase the number of immune system cells (called T cells or CD4+ T-cells). Both of these changes are associated with healthier immune systems and decreased likelihood of serious illness.

bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: